{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:40:47Z","timestamp":1767894047856,"version":"3.49.0"},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While traditional immunosuppressive and immunomodulatory therapies remain the cornerstone of immune\u2010mediated neuromuscular disease management, new and novel agents including antigen\u2010specific, monoclonal antibody drugs, have emerged as important treatment options. This article is the second of a two\u2010part series that reviews immune\u2010based therapies in neuromuscular diseases. The first article provides an update on the use of traditional immune\u2010based therapies such as corticosteroids, plasma exchange, steroid\u2010sparing immunosuppressive drugs, and intravenous immunoglobulin G. This second article focuses on new and novel immune\u2010based therapies, including eculizumab, a complement inhibitor approved for acetylcholine receptor antibody\u2010positive myasthenia gravis; rituximab, a B\u2010cell depletion therapy with evolving indications in neuromuscular diseases; and the subcutaneous formulation of immunoglobulin G that gained approval for use in chronic inflammatory demyelinating polyradiculoneuropathy in 2018. Finally, several novel antigen\u2010specific drugs at different stages of investigation in neuromuscular disease are also reviewed.<\/jats:p>","DOI":"10.1002\/mus.26711","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T07:15:26Z","timestamp":1568790926000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents"],"prefix":"10.1002","volume":"61","author":[{"given":"Constantine","family":"Farmakidis","sequence":"first","affiliation":[{"name":"Neurology Department The University of Kansas Medical Center  Kansas City Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[{"name":"Neurology Department The University of Kansas Medical Center  Kansas City Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamatha","family":"Pasnoor","sequence":"additional","affiliation":[{"name":"Neurology Department The University of Kansas Medical Center  Kansas City Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[{"name":"Neurology Department The University of Kansas Medical Center  Kansas City Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327115603594"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26070"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51301.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(93)90103-N"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26114"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000034"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_2_7_14_1","volume-title":"Zilucoplan, a subcutaneously self\u2010administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: results of a phase 2 randomized, double\u2010blind, placebo\u2010controlled trial and open\u2010label long\u2010term extension","author":"Howard JF","year":"2019"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.08.007"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.7.1062-a"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23412"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005692"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26107"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2016-2"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00911.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23794"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000205"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000149"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004773"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21577"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318296e92b"},{"key":"e_1_2_7_32_1","first-page":"Cd002827","article-title":"Immunotherapy for IgM anti\u2010myelin\u2010associated glycoprotein paraprotein\u2010associated peripheral neuropathies","volume":"10","author":"Lunn MP","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2009.04.013"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00270.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34331"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2013.05.004"},{"key":"e_1_2_7_40_1","unstructured":"Gamunex\u2010C Prescription Drug Labeling[Internet]. [cited July 30 2019].https:\/\/www.fda.gov\/files\/vaccines %20blood%20&%20biologics\/published\/Package-Insert\u2013Gamunex-C.pdf. Accessed August 30 2019."},{"key":"e_1_2_7_41_1","unstructured":"Gammagard Liquid Prescription Drug Labeling[Internet]. [cited June 30 2019].https:\/\/www.fda.gov\/media\/70812\/download. Accessed September 4 2019."},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9002-x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90147-H"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-8905-x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13218"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30378-2"},{"issue":"12","key":"e_1_2_7_47_1","first-page":"Cd001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Eftimov F","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25107"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7444-2"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25409"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159993"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004365"},{"issue":"2","key":"e_1_2_7_53_1","first-page":"S116","article-title":"2018 AANEM Annual Meeting Abstract Guide Washington, DC, October 10\u201313, 2018: subcutaneous immunoglobulin in myasthenia gravis: a North American open label study","volume":"58","author":"Dimachkie MM","year":"2018","journal-title":"Muscle Nerve"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_7_57_1","unstructured":"UCB Accelerates Anti\u2010FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase[Internet]. [cited Septmber 7 2019].https:\/\/www.prnewswire.com\/news-releases\/ucb-accelerates-anti-fcrn-rozanolixizumab-in-myasthenia-gravis-into-confirmatory-development-phase-818635422.html. Accessed September 7 2019."},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-018-0521-6"},{"key":"e_1_2_7_59_1","first-page":"17","article-title":"Novel treatments in the management of myositis","author":"Hamasaki A","year":"2019","journal-title":"Accessed September"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211751"},{"key":"e_1_2_7_62_1","unstructured":"SolirisREMS(Risk evaluation and mitigation strategy). [cited July 7 2019].https:\/\/www.solirisrems.com\/. Accessed September 4 2019."}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.26711","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.26711","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.26711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T23:40:54Z","timestamp":1693870854000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.26711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/mus.26711"],"URL":"https:\/\/doi.org\/10.1002\/mus.26711","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"2019-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}